ArticleWorld journal of surgical oncology2025
Clinical study of separation surgery combined with intraoperative vertebroplasty and
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThe study aim was to evaluate the efficacy and safety of separation surgery combined with intraoperative vertebroplasty and
methodsWe retrospectively analyzed patients with lung adenocarcinoma spinal metastases who were treated for epidural spinal cord compression. Patients were divided into the SSVPI group (Separation surgery + vertebroplasty +
resultsAll 96 patients underwent the surgery successfully. The baseline characteristics showed no significant between the two groups. The SSVPI group demonstrated superior outcomes, with better neurological recovery(Higher International Standards for Neurological Classification of Spinal Cord Injury grade D improvement; >40% at 1/3/6 months, P<0.005). Pain relief (Faster visual analog scale pain score reduction;>60% decline within 2 months, P<0.001), and improved performance status (Earlier ECOG/KPS improvement;≥75% by 2 weeks). Quality of life, assessed by Quality of Life Questionnaire-Core 30 scores increased by 18.6 points at 3 months (P≤0.003).The SSVPI group also experienced longer median overall survival (20 vs. 12 months, P=0.026), progression-free survival (12 vs. 8 months), and local control (all P<0.05). The SSVPI group primarily experienced minor bone cement leakage (10.42%)), whereas the control group experienced complications predominantly related to tumor progression-associated secondary spinal cord compression (3 cases, 6.25%) and radiation therapy-related adverse events (total incidence: 39.6%), including radiation dermatitis (18.75%), osteonecrosis (16.67%), and spinal cord injury (4.17%).
conclusionSSVPI is an optimized treatment for lung adenocarcinoma-related MESCC. It provides immediate spinal cord decompression and stabilization, concurrent intraoperative
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.